Jung, J; Eggleton, P; Robinson, A; Wang, J; Gutowski, N; Holley, J; Newcombe, J; ... Michalak, M; + view all Jung, J; Eggleton, P; Robinson, A; Wang, J; Gutowski, N; Holley, J; Newcombe, J; Dudek, E; Paul, AM; Zochodne, D; Kraus, A; Power, C; Agellon, LB; Michalak, M; - view fewer (2018) Calnexin is necessary for T cell transmigration into the central nervous system. JCI Insight , 3 (5) , Article e98410. 10.1172/jci.insight.98410.

Preview	Text (Article) Newcombe_98410.1-20180315203546-covered-253bed37ca4c1ab43d105aefdf7b5536.pdf - Published Version Download (1MB) | Preview
Preview	Text (Supplemental data) Newcombe_jci.insight.98410.sd.pdf - Published Version Download (1MB) | Preview

Abstract

In multiple sclerosis (MS), a demyelinating inflammatory disease of the CNS, and its animal model (experimental autoimmune encephalomyelitis; EAE), circulating immune cells gain access to the CNS across the blood-brain barrier to cause inflammation, myelin destruction, and neuronal damage. Here, we discovered that calnexin, an ER chaperone, is highly abundant in human brain endothelial cells of MS patients. Conversely, mice lacking calnexin exhibited resistance to EAE induction, no evidence of immune cell infiltration into the CNS, and no induction of inflammation markers within the CNS. Furthermore, calnexin deficiency in mice did not alter the development or function of the immune system. Instead, the loss of calnexin led to a defect in brain endothelial cell function that resulted in reduced T cell trafficking across the blood-brain barrier. These findings identify calnexin in brain endothelial cells as a potentially novel target for developing strategies aimed at managing or preventing the pathogenic cascade that drives neuroinflammation and destruction of the myelin sheath in MS.

Download activity - last month

Export as CSVJSONXML

Download activity - last 12 months

Export as XMLJSONCSV

Downloads by country - last 12 months

Export as CSVJSONXML

Archive Staff Only

View Item